IPBronch.com | Interventional Pulmonology

🎯 Background & Rationale

Parapneumonic effusion (PPE) is a common and potentially life-threatening complication of pneumonia that can progress from uncomplicated PPE (UPPE) to complicated PPE (CPPE) and empyema, requiring invasive interventions like chest tubes or video-assisted thoracoscopic surgery (VATS). The molecular mechanisms and biomarkers driving this disease progression remain poorly characterized, limiting early risk stratification and targeted therapy.

👥 Study Design & Population

This is a Prospective Transcriptomic and Proteomic Discovery-Validation Cohort Study evaluating patients with pleural effusions.

Discovery Cohort: 26 PPE patients stratified by disease severity into non-severe PPE (UPPE, n = 9) and severe PPE (CPPE, n = 12; empyema, n = 5) who underwent capture-based targeted RNA sequencing.
Validation Cohort: 220 patients with various pleural effusion etiologies (non-PPE controls including transudates, other exudates, and malignancy, n = 120; PPE patients, n = 100) evaluated via enzyme-linked immunosorbent assay (ELISA) for HMGB2 levels.
In Vitro Models: Human (HL-60, THP-1) and murine primary neutrophils and macrophages infected with Streptococcus pneumoniae or stimulated with peptidoglycan (PGN) to characterize HMGB2 functional relevance.

📈 Methodology & Rigor

The study integrated whole-transcriptome RNA sequencing of pleural effusion cells with previously generated proteomic secretome and cytokine datasets. Differentially expressed genes (DEGs) were identified using DESeq2, and functional enrichment was mapped via IPA, KEGG, and Gene Ontology. Biomarker diagnostic accuracy was assessed using receiver operating characteristic (ROC) curves and area under the curve (AUC) analysis. In vitro cell models assessed mechanistic pathways via qRT-PCR, Western blotting, flow cytometry, ELISA, and NF-κB luciferase reporter assays.

🔬 Key Findings [or Planned Endpoints]

Transcriptomic Signatures: Severe PPE demonstrated 232 upregulated and 212 downregulated genes compared to non-severe PPE, with enrichment in neutrophil degranulation, glycolysis, HIF-1 signaling, and inflammatory cytokine pathways. Empyema showed further upregulation of interferon signaling, pyroptosis, and NET formation compared to CPPE.
HMGB2 as a Biomarker: Integrating transcriptomic and secretome data identified High-Mobility Group Box 2 (HMGB2) as a key upregulated candidate. Pleural HMGB2 accurately discriminated severe PPE from other pleural effusions with an AUC of 0.93 (sensitivity 94.0%, specificity 84.7% at a cutoff of 155 pg/ml).
Cellular & Molecular Mechanisms: S. pneumoniae infection significantly upregulated HMGB2, IL-1β, and IL-8 in neutrophils and macrophages. HMGB2 overexpression enhanced NF-κB promoter activation and increased IL-1β and IL-8 expression in PGN-stimulated macrophages.

⚖️ Critical Appraisal

The study provides a robust, multi-omics approach combining human tissue transcriptomics, secretomics, large-scale clinical validation (n=220), and mechanistic in vitro functional assays. However, limitations include the modest size of the discovery sequencing cohort (n=26), potential confounding effects of prior antibiotic administration on transcriptomic profiles, and the need for broader multi-center validation across diverse bacterial pathogens beyond S. pneumoniae.

💡 The Clinical Bottom Line

Pleural HMGB2 emerges as a promising, highly sensitive biomarker capable of accurately distinguishing severe complicated PPE/empyema from non-severe effusions and malignant fluids. In the interventional pulmonology suite, this finding sets the stage for utilizing pleural fluid biomarkers for early risk stratification, potentially identifying patients with pneumonia who require aggressive early interventions (such as early indwelling tunneled pleural catheters, fibrinolytics, or medical thoracoscopy) before extensive pleural peel formation occurs.

BACKGROUND: Parapneumonic effusion (PPE) exacerbation is associated with high morbidity and mortality in pneumonia patients. However, the molecular signatures underlying the progression and severity of PPE remain poorly understood. We therefore employed whole-transcriptome profiling to comprehensively characterize the molecular landscape associated with PPE exacerbation and its clinical manifestations. METHODS: In the discovery cohort, 26 PPE patients underwent capture-based targeted RNA sequencing and were stratified by disease severity into non-severe PPE (UPPE, n = 9) and severe PPE (n = 17), comprising CPPE (n = 12) and empyema (n = 5). Bioinformatic functional annotation was performed to delineate gene expression signatures associated with disease progression from non-severe to severe PPE. Integrated analyses of the transcriptome and secretome of pleural effusions identified high-mobility group box 2 (HMGB2) as a novel biomarker for severe PPE. In the validation cohort, 220 patients with different pleural effusion etiologies were enrolled for enzyme-linked immunosorbent assay (ELISA) analysis to evaluate HMGB2 levels. The functional relevance of HMGB2 in PPE progression was characterized in neutrophils and macrophages. RESULTS: In pneumonia patients, severe PPE was associated with higher expression of 232 genes and lower expression of 212 genes compared with non-severe PPE. Upregulated gene signatures associated with disease progression in severe PPE were enriched in neutrophil degranulation, glycolysis/gluconeogenesis, HIF-1 signaling, and inflammatory response pathways. Elevated HMGB2 levels in severe PPE enabled accurate discrimination from other pleural effusion cases, with an AUC of 0.93. In vitro infection with Streptococcus pneumoniae significantly increased HMGB2, IL1β, and IL8 expression in neutrophils and macrophages. Moreover, HMGB2 overexpression enhanced NF-κB activation as well as IL-1β and IL-8 levels in PGN-stimulated macrophages. These results suggest that HMGB2 regulates IL-1β and IL-8 via the NF-κB signaling pathway. CONCLUSIONS: Our study delineates molecular signatures driving PPE exacerbation and highlights HMGB2 as a novel biomarker and therapeutic target with potential to prevent severe PPE.